August 17, 2026 – Aetna is entering the 2027 Medicare Advantage selling season amid a broader industry shift that is putting pressure on the traditional relationship between Medicare Advantage insurers and the independent agents and brokers who help seniors select coverage.

While headlines may suggest that Aetna is simply “cutting Medicare Advantage commissions,” the reality is more nuanced. Aetna has already designated certain Medicare Advantage products as non-commissionable for new sales in selected markets, and the company’s approach to 2027 comes as insurers across the industry reassess which plans they want to grow. The result is a changing compensation environment that could have significant consequences for brokers, insurance agencies and, potentially, Medicare beneficiaries.

A Changing Medicare Advantage Business Model

Medicare Advantage has become an increasingly competitive business. More than half of Medicare beneficiaries are now enrolled in Medicare Advantage, and insurers have spent years competing aggressively for new members.

That growth strategy has become more difficult as medical costs, utilization and other expenses rise. For 2027, the Centers for Medicare & Medicaid Services (CMS) finalized an average 2.48% increase in Medicare Advantage payments to plans, equivalent to more than $13 billion in additional payments. When estimated risk-score trends are included, CMS projects a 4.98% increase.

Despite that increase, insurers continue to scrutinize the profitability of individual products and markets.

The result is a growing willingness to reduce marketing expenditures, withdraw from selected counties, redesign benefits and, in some cases, reduce or eliminate compensation paid to independent agents.

Aetna Has Already Used Non-Commissionable Plans

Aetna’s commission strategy did not begin with 2027.

Aetna’s producer materials have previously identified selected Medicare Advantage plans as non-commissionable for new business while continuing renewal compensation on eligible existing business. The company’s 2025 Medicare producer materials also stated that new sales of standalone Part D plans were non-commissionable nationwide, while renewal commissions continued on previously placed commissionable business.

Industry research likewise documents Aetna’s earlier use of non-commissionable Medicare Advantage products in selected states and plan types.

That distinction is important. A non-commissionable plan does not mean that the plan is unavailable to Medicare beneficiaries. It means that an independent agent may receive little or no compensation for placing a new member into that particular product.

The 2027 Commission Picture Is More Complicated

There is an important counterpoint to the story of commission reductions: CMS has actually increased the maximum allowable compensation for 2027.

Industry sources report that the national maximum initial compensation for Medicare Advantage is rising from $694 in 2026 to $725 in 2027, while maximum renewal compensation is generally half of the initial amount. Certain regions have higher limits.

But the CMS maximum is not a guarantee that every insurer will pay the maximum amount on every plan.

CMS requires Medicare Advantage organizations using independent agents to report the compensation amounts or ranges they pay. CMS guidance makes clear that plans operate within the applicable federal compensation limits rather than being required to pay the maximum on every enrollment.

Consequently, a higher federal compensation ceiling does not necessarily translate into higher income for every Medicare agent.

Why Would Aetna Reduce Commissions?

The underlying issue is economics.

When an insurer stops paying commissions on a particular plan, it can reduce the cost associated with acquiring new members. That can be particularly attractive for plans that are already growing rapidly or that have become less profitable because of higher medical utilization.

MedPAC’s 2026 report to Congress noted that insurers have been stopping commission payments on selected Medicare Advantage products and markets. The report specifically cited Aetna, Cigna and Elevance among insurers that stopped offering commissions on certain plans during the 2024 enrollment period.

The practice is therefore not unique to Aetna. It reflects a broader effort by Medicare Advantage organizations to manage membership growth and profitability.

What It Means for Independent Agents

For Medicare agents, the change creates a difficult balancing act.

An agent’s responsibility is to recommend coverage based on the beneficiary’s needs, including physicians, hospitals, prescription drugs, premiums, cost-sharing, networks and supplemental benefits. Compensation should not determine the recommendation.

However, eliminating commissions can create an economic problem for independent brokers who spend substantial time educating consumers, comparing plans, completing compliance requirements and assisting with enrollment.

Aetna itself continues to emphasize its relationship with brokers. Its current Medicare broker-support site describes brokers as an important part of its distribution strategy and provides resources for certification, enrollment and sales support.

The challenge is that the list of plans an agent can sell and the list of plans that compensate the agent are not necessarily identical.

Potential Impact on Medicare Beneficiaries

For consumers, the commission issue may be largely invisible.

A senior could meet with an independent agent, discuss several Medicare Advantage options and ultimately choose a plan that does not compensate the agent.

That creates a potential tension in the distribution system. If agents receive no compensation for certain plans, some may have less financial incentive to market those products, even when they could be appropriate for a particular beneficiary.

At the same time, CMS has been tightening rules intended to prevent compensation arrangements from encouraging agents to steer consumers toward plans based on financial incentives rather than their healthcare needs. CMS previously described its compensation reforms as an effort to ensure that agents and brokers are paid for legitimate enrollment-related activities without creating incentives for anti-consumer steering.

The policy challenge is therefore two-sided: regulators want to prevent commissions from influencing recommendations, while beneficiaries also need access to qualified professionals who can help them navigate an increasingly complicated Medicare market.

2027 Could Be a Pivotal Year

The commission controversy comes as Medicare Advantage itself is entering a period of adjustment.

Several major insurers are reducing their Medicare Advantage footprints or reassessing markets for 2027. Recent industry reporting indicates that insurers are increasingly prioritizing profitability and sustainability over simply adding members.

For brokers, that means the 2027 Annual Enrollment Period could look very different from the rapid-growth years of Medicare Advantage.

Aetna’s 2027 product information is already being made available to contracted producers through its First Look platform, although Aetna cautions that plan designs and service areas remain subject to government approval and can change.

CMS also reported that 2027 compensation information was due from plans through its Health Plan Management System by July 31, 2026.

That information will be increasingly important for agents trying to understand which plans will be financially sustainable to sell.

The Bottom Line

Aetna’s approach to Medicare Advantage commissions should not be characterized simply as an across-the-board pay cut for all agents. The more significant development is the continued expansion of plan-specific and market-specific compensation decisions.

For brokers, the message is clear: knowing the Medicare Advantage market in 2027 will require more than knowing which carriers offer plans in a particular ZIP code. Agents will need to understand which plans are commissionable, which are not, what renewal compensation applies and whether a carrier has changed its strategy in a particular county.

For Medicare beneficiaries, the most important safeguard remains the same: choose coverage based on healthcare needs rather than an agent’s compensation.

As Aetna and other insurers enter the 2027 selling season, the central question will not simply be how much Medicare Advantage plans pay agents. It will be whether the evolving compensation model can preserve broad consumer choice while allowing insurers, brokers and beneficiaries to operate in a market under increasing financial pressure.